1. Scrip
  2. >>Business
  3. >>Strategy

Altimmune Outlines Pemvidutide Plans In MASH And Beyond

 
• By Joseph Haas

The company sees potential for the GLP-1/glucagon receptor dual agonist in MASH as well as alcohol-related liver disease as hopes to move pemvidutide into Phase III in obesity with a partner.

Liver care
Altimmune will study its MASH candidate in alcohol-related liver disease • Source: Shutterstock

Altimmune highlighted a broad range of target indications for its “pipeline-in-a-product” candidate pemvidutide in a 13 March R&D Day presentation for investors and analysts that could expand the dual GLP-1/glucagon receptor agonist’s reach far beyond its most advanced indications of metabolic dysfunction-associated steatohepatitis (MASH) and obesity.

Key Takeaways
  • Altimmune made a case for its dual GLP-1/glucagon receptor agonist pemvidutide in multiple diseases at an investor day, including MASH and obesity.

The company described the drug as Phase III-ready in obesity, soon to report Phase IIb histology data in MASH and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Supernus Secures Sage With CVR-Supported Deal

 
• By Jessica Merrill

Supernus agreed to pay $561m upfront plus a contingent value right that could add $234m to buy Sage, topping a previously rejected offer from Biogen.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

More from Therapy Areas

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.